Will Eli Lilly (LLY) Q3 Mounjaro sales be above __?

Polymarket Finance › Companies Closes Thu 9:30 AM ET · $25 today · $4.5K traded · $1.8K at stake · prices read 33 min ago

The odds

$11.07Bmedian
$8B$14B
Median $11.07BMiddle half $10.31B – $11.82B

How the odds have moved

Median: $10.58B on Oct 20, $11.07B now.

The median the market implied over time and its middle half (the band), read from every strike's prices on Polymarket.

Every outcome

Outcome Chance Day Bid Ask Pays Traded
$9B 85% ▼ 4 78¢ 92¢ $1.09 $933
$10B 85% ▲ 2 81¢ 89¢ $1.12 $1.5K
$11B 53% ▼ 1 33¢ 72¢ $1.39 $355
$12B 19% 14¢ 24¢ $4.17 $605
$13B 9% 3¢ 15¢ $6.67 $1.1K

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: Eli Lilly, Mounjaro

Search ›
  • Eli Lilly Joins Moonwalk’s $70M Series B Roundgenomeweb.com · 29 h agoMoonwalk Biosciences said it will use the funds to advance its lead candidate for obesity, MW101, into clinical testing by late 2027. Eli Lilly Joins Moonwalk’s $70M Series B Round to Fund Cardiometabolic RNAi Drugs NEW YORK – Moonwalk…
  • Eli Lilly and Company $LLY Stock Holdings Raised by XXI Wealth LLCMarkets Daily · 28 h agoPosted by Kim Johansen on Oct 26th, 2026 Check Out Our Latest Analysis on LLY Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical…
  • Eli Lilly (LLY) Stock: Olomorasib Shows 62% Response Rate in Lung Cancer DataCoinCentral · 29 h agoEli Lilly (LLY) shared new lung cancer data on Sunday. The company presented results for its experimental drug olomorasib at the 2026 European Society for Medical Oncology congress in Madrid. The release did not include a stock price move…
  • Eli Lilly Says Olomorasib Shows 'Durable Efficacy' in Non-Small Cell Lung Cancer StudiesYahoo Finance · 37 h agoEli Lilly (LLY) said new trial data showed olomorasib delivered durable first-line activity in patients with KRAS 12. Results from a phase 1/2 study and a phase 3 study showed olomorasib combined with ... Oops, something went wrong U.S…
  • Eli Lilly (LLY) Stock: Lung Cancer Drug Olomorasib Posts 62% Response Rate at ESMOMoneyCheck · 24 h agoEli Lilly (LLY) put fresh lung cancer data on the table Sunday at the European Society for Medical Oncology congress in Madrid. The focus was olomorasib, its experimental KRAS G12C inhibitor. Eli Lilly and Company, LLY One study tested the…
  • Eli Lilly Stock Gets a Lift as New Lung Cancer Data Raises HopesYahoo Finance · 37 h agoEli Lilly (NYSE:LLY) shares climbed nearly 1% in pre-market trading after clinical data showed its experimental drug olomorasib shrank tumors in 62% of patients when paired with immunotherapy and chemotherapy for an aggressive form of lung…
  • Eli Lilly (LLY) Reports Strong Phase 1 Ovarian Cancer DataYahoo Finance · 48 h agoEli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients. The regimen showed a high confirmed response rate and disease control rate in both PARP inhibitor-experienced and…
  • 3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 2924/7 Wall St. · 47 h agoEli Lilly (NYSE:LLY | LLY Price Prediction) reports third-quarter results on October 29. It brings a streak of 5 consecutive EPS beats and a stock that has run hard into the report. I’m watching three catalysts that could keep the rally…
  • Eli Lilly reports promising lung cancer drug resultsSeeking Alpha · 2 days agoLilly’s olomorasib showed promising lung cancer trial results, boosting its KRAS G12C treatment outlook ahead of key Phase 3 data. jetcityimage/iStock Editorial via Getty Images Eli Lilly (LLY) reported encouraging results from clinical…
  • Lilly declares fourth-quarter 2026 dividend@PRNewswire · 23 h ago/PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on... Oct 26, 2026, 11:19 ET The dividend is payable on December 10, 2026, to…
  • Eli Lilly releases promising early-stage data on ADC for ovarian cancerSeeking Alpha · 3 days agoPhase 1 data show Eli Lilly’s Sofe-M plus Avastin delivered strong ovarian cancer response rates across FRα levels. Read more here. - Phase 1 data on Eli Lilly's (LLY) sofetabart mipitecan (Sofe-M) found that the antibody-drug conjugate…
  • Baylor Scott & White app now has Arianna Huffington's Thrive GlobalAustin American-Statesman · 25 h agoThe MyBSWHealth app from Baylor Scott & White will have embedded information from Thrive Global to focus on preventive health tips, not just emergent health needs. People who have the Baylor Scott & White Health app might have noticed some…

Related markets

All companies ›

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Conservative. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Conservative, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Conservative index; prices of stocks, rates and coins from 4Conservative Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions